Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
NA
Niagen Bioscience, Inc. Common Stock
NAGE
Mkt Cap
$196.7M
Volume
499.12K
Next Earnings
November 3rd
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
NA
NAGE
NA
Niagen Bioscience, Inc. Common Stock
NAGE
News
·
Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion— Stock Jumps After-Hours (UPDATED)
Mkt Cap
$204.1M
Volume
499.12K
Next Earnings
November 3rd
Chart
Financials
Earnings
News
About
Insider
Filings
Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion— Stock Jumps After-Hours (UPDATED)
Niagen Bioscience (NASDAQ: NAGE) reported doubled annual profits and 30% revenue growth for 2025, reaching $129.4 million in net sales. CEO Rob Fried announced the company is actively pursuing acquisitions and expanding into new markets including at-home injection kits and cosmetics partnerships. However, 2026 guidance of $145 million (15% growth) appears more modest, and the stock trades 60% below its 52-week high despite strong fundamentals.
Benzinga · Mar 5, 2026
National Advertising Division Finds Certain Reus Cata-Kor NAD+ Claims Supported; Recommends Others Be Modified or Discontinued
The National Advertising Division reviewed claims by Reus Research for its Cata-Kor NAD+ products, finding some claims supported while recommending modifications or discontinuation of others due to insufficient substantiation of health benefits and inadequate influencer disclosures.
GlobeNewswire Inc. · Oct 13, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
NA
NAGE
Niagen Bioscience, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
NAGE
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any NAGE yet.
Related Tickers
Earnings